Connor, Clark & Lunn Investment Management (CC&L)’s Immunic IMUX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,003	Closed	-$131K	–	1592
2025 Q1	$131K	Sell	12,003 -3,914	-25%	-$42.3K	﹤0.01%	1346
2024 Q4	$159K	Buy	15,917 +5,691	+56%	+$71.7K	﹤0.01%	1345
2024 Q3	$169K	Buy	10,226 +4,239	+71%	+$60.4K	﹤0.01%	1338
2024 Q2	$66.5K	Buy	5,987 +33	+0.6%	+$410	﹤0.01%	1325
2024 Q1	$78.6K	Buy	+5,954	New	+$77.4K	﹤0.01%	1475
2023 Q4	–	Sell	-2,477	Closed	-$36.4K	–	1468
2023 Q3	$36.4K	Sell	2,477 -8,274	-77%	-$159K	﹤0.01%	1324
2023 Q2	$270K	Buy	10,751 +2,060	+24%	+$34.5K	﹤0.01%	1129
2023 Q1	$129K	Buy	+8,691	New	+$161K	﹤0.01%	1135

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IMUX Position: Q2 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Immunic (IMUX) in Q2 2025, closing a stake of 12,003 shares — an estimated $131K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IMUX in Q1 2023 and held it in 8 quarters. The position peaked at $270K in Q2 2023. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Immunic position as of Q2 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 12,003 Immunic shares in Q2 2025, an estimated $131K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Immunic in Q1 2023 and held it in 8 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Immunic position peaked at $270K in Q2 2023.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2025, filed 7 Aug 2025.